论文部分内容阅读
目的 :通过检测幽门螺旋杆菌毒素抗体UreC、CagA决定慢性胃炎患者HP治疗的时机和方式。方法 :对 2 10例HP阳性慢性胃炎患者 ,根据CagA结果 ,分别给予不治疗、同时治疗、两阶段治疗 ,并调查各组患者的依从性、有效率。结果 :不给予HP根治的UreC( +)CagA( -)组依从性显著高于进行HP根治的UreC( +)CagA( +)组 (P <0 .0 1) ,但两阶段根治组的依从性与UreC( +)CagA( -)组无显著性差异 (P >0 .0 5 )。各组的有效率无显著性差异 (P >0 .0 5 )。结论 :可根据生物蛋白芯片技术检测的UreC、Ca gA的结果 ,决定慢性胃炎HP阳性患者是否需HP根治治疗以及治疗的时机 ,并认为分阶段进行治疗可提高患者的依从性 ,使治疗得以完成。
Objective: To determine the timing and mode of HP therapy in chronic gastritis patients by detecting H. pylori antibody UreC and CagA. Methods: Twenty-one patients with HP-positive chronic gastritis were treated with no treatment, concurrent treatment and two-stage treatment according to the results of CagA, and the compliance and efficiency of each group were investigated. Results: The compliance of UreC (+) CagA (-) group without HP was significantly higher than that of UreC (+) CagA (+) group without HP (P <0.01), but the two groups There was no significant difference between UreC (+) CagA (-) and sex (P> 0.05). The efficiency of each group was no significant difference (P> 0.05). Conclusion: According to the results of UreC and Ca gA detected by bioprotein chip technology, we can decide whether HP-positive patients with chronic gastritis need HP radical treatment and the timing of treatment. It is considered that the phased treatment can improve patient compliance and make the treatment complete .